NTRA
NEUTRAL
$207.19
Live
Natera, Inc. · NASDAQ
Target $258.58
(+24.8%)
$131.81
52W Range
$256.36
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$29.37B
P/E
N/A
ROE
-14.3%
Profit margin
-9.0%
Debt/Equity
0.13
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
NTRA exhibits a stark disconnect between its operational growth and its financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company demonstrates impressive revenue growth of 39.8% and strong gross margins (64.75%), it remains unprofitable with a negative forward P/E and extreme valuation multiples (P/S 12.73, P/B 16.90). The bullish analyst consensus is heavily countered by bearish insider activity, with $45.05M in sales and zero buys over the last six months. Consequently, the stock is a high-risk growth play where valuation is based on future expectations rather than current fundamental strength.
Key Strengths
Strong top-line revenue growth (39.8% YoY)
Robust gross margins at 64.75%
Excellent short-term liquidity with a current ratio of 3.39
Low leverage with a Debt/Equity ratio of 0.13
Strong analyst backing with a 'strong_buy' consensus and target price of $258.58
Key Risks
Poor financial health indicated by a Piotroski F-Score of 2/9
Extreme valuation premiums (Price/Book of 16.90)
Persistent lack of profitability (Profit Margin -9.03%)
Significant insider selling ($45.05M) suggesting a lack of confidence at current levels
Negative forward earnings expectations (Forward P/E -305.11)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
35
Weak
15
80
50
30
0
AI Verdict
Speculative Growth
Key drivers: Revenue Growth, Piotroski F-Score, Insider Selling, Valuation Multiples
Confidence
90%
Value
15/100
Graham Number and Intrinsic Value are unavailable due to negative earnings; stock trades at a massive growth premium.
Positives
No standout positives identified.
Watchpoints
- P/S of 12.73 is excessive
- P/B of 16.90 indicates extreme premium
- Negative Forward P/E
Future
80/100
Growth rates are the primary driver of the current stock price.
Positives
- 39.8% YoY Revenue Growth
- Strong analyst target price ($258.58)
- Recent Q/Q EPS growth surge (+156.2%)
Watchpoints
- Uncertainty in timing of GAAP profitability
Past
50/100
Historical trend shows a company scaling rapidly but struggling to convert revenue to net income.
Positives
- Consistent revenue expansion
- Strong 3Y price performance (+306.2%)
Watchpoints
- Long history of negative earnings surprises
Health
30/100
While solvent and liquid, the operational efficiency and profitability metrics are poor.
Positives
- Low Debt/Equity (0.13)
- High Current Ratio (3.39)
Watchpoints
- Piotroski F-Score of 2/9 indicates weak fundamental health
Dividend
0/100
Company is in a growth phase and does not return capital to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$207.19
Analyst Target
$258.58
Upside/Downside
+24.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NTRA and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NTRA
Natera, Inc.
Primary
|
+93.7% | +306.2% | +36.5% | +15.5% | +4.8% | -1.7% |
|
BIIB
Biogen Inc.
Peer
|
-34.2% | -34.1% | +34.0% | +30.9% | -2.5% | -0.3% |
|
GEHC
GE HealthCare Technologies Inc.
Peer
|
+22.2% | -9.0% | +12.5% | -1.6% | +0.3% | +3.6% |
|
INSM
Insmed Incorporated
Peer
|
+402.3% | +817.7% | +138.9% | -4.6% | +11.1% | -4.7% |
|
DXCM
DexCom, Inc.
Peer
|
-31.7% | -50.1% | -22.2% | -32.1% | -11.2% | +5.6% |
NTR
Natera, Inc.
Primary
5Y
+93.7%
3Y
+306.2%
1Y
+36.5%
6M
+15.5%
1M
+4.8%
1W
-1.7%
BII
Biogen Inc.
Peer
5Y
-34.2%
3Y
-34.1%
1Y
+34.0%
6M
+30.9%
1M
-2.5%
1W
-0.3%
GEH
GE HealthCare Technologies Inc.
Peer
5Y
+22.2%
3Y
-9.0%
1Y
+12.5%
6M
-1.6%
1M
+0.3%
1W
+3.6%
INS
Insmed Incorporated
Peer
5Y
+402.3%
3Y
+817.7%
1Y
+138.9%
6M
-4.6%
1M
+11.1%
1W
-4.7%
DXC
DexCom, Inc.
Peer
5Y
-31.7%
3Y
-50.1%
1Y
-22.2%
6M
-32.1%
1M
-11.2%
1W
+5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-305.11
PEG Ratio
N/A
P/B Ratio
16.9
P/S Ratio
12.73
EV/Revenue
12.82
EV/EBITDA
-108.9
Market Cap
$29.37B
Profitability
Profit margins and return metrics
Profit Margin
-9.03%
Operating Margin
-3.42%
Gross Margin
64.75%
ROE
-14.32%
ROA
-9.54%
Growth
Revenue and earnings growth rates
Revenue Growth
+39.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+39.79%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.13
Low debt
Current Ratio
3.39
Strong
Quick Ratio
3.11
Excellent
Cash/Share
$7.59
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.7B
Gross Margin
66.9%
Op. Margin
-3.4%
Net Margin
7.1%
Total Assets
$2.4B
Liabilities
$0.7B
Equity
$1.7B
Debt/Equity
0.40x
Operating CF
$0.1B
CapEx
$-0.1B
Free Cash Flow
$0.0B
FCF Yield
23%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$0.36
+167.5% surprise
2025-11-06
$-0.64
-80.7% surprise
2025-08-07
$-0.74
-24.5% surprise
Healthcare Sector Comparison
Comparing NTRA against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-14.32%
This Stock
vs
-100.15%
Sector Avg
-85.7%
(Below Avg)
Profit Margin
-9.03%
This Stock
vs
-13.63%
Sector Avg
-33.8%
(Weaker)
Debt to Equity
0.13
This Stock
vs
3.22
Sector Avg
-96.1%
(Less Debt)
Revenue Growth
39.8%
This Stock
vs
121.05%
Sector Avg
-67.1%
(Slower)
Current Ratio
3.39
This Stock
vs
4.55
Sector Avg
-25.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NTRA
Natera, Inc.
|
NEUTRAL | $29.37B | - | -14.3% | -9.0% | $207.19 | |
|
BIIB
Biogen Inc.
|
NEUTRAL | $26.91B | 20.83 | 7.4% | 13.1% | $183.33 | Compare |
|
GEHC
GE HealthCare Technologies Inc.
|
NEUTRAL | $33.27B | 16.2 | 22.4% | 10.1% | $72.91 | Compare |
|
INSM
Insmed Incorporated
|
BEARISH | $33.42B | - | -249.3% | -210.5% | $154.81 | Compare |
|
DXCM
DexCom, Inc.
|
BULLISH | $23.29B | 32.26 | 30.6% | 16.0% | $58.06 | Compare |
NTRA
Natera, Inc.
NEUTRAL
Mkt Cap
$29.4B
P/E
-
ROE
-14.3%
Price
$207.19
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | RABINOWITZ MATTHEW | Officer and Director | Option Exercise | 58,292 | $559,020 |
| 2026-04-01 | MOSHKEVICH SOLOMON | Officer | Sale | 3,000 | $606,899 |
| 2026-04-01 | RABINOWITZ DANIEL A | Officer | Sale | 8,400 | $1,707,814 |
| 2026-03-31 | RABINOWITZ MATTHEW | Officer and Director | Option Exercise | 41,708 | $399,980 |
| 2026-03-20 | SHEENA JONATHAN | Director | Sale | 4,570 | $908,301 |
| 2026-03-16 | RABINOWITZ MATTHEW | Officer and Director | Sale | 200,000 | $38,283,382 |
| 2026-03-16 | RABINOWITZ MATTHEW | Officer and Director | Option Exercise | 200,000 | $1,918,000 |
| 2026-03-13 | CHAPMAN ROWAN E | Director | Sale | 122 | $23,348 |
| 2026-03-10 | MOSHKEVICH SOLOMON | Officer | Sale | 915 | $186,781 |
| 2026-03-10 | CHAPMAN STEVEN LEONARD | Chief Executive Officer | Sale | 5,623 | $1,147,838 |
| 2026-03-10 | RABINOWITZ DANIEL A | Officer | Sale | 1,745 | $356,212 |
| 2026-03-10 | SHEENA JONATHAN | Director | Sale | 127 | $25,925 |
| 2026-03-10 | BROPHY MICHAEL BURKES | Chief Financial Officer | Sale | 785 | $160,244 |
| 2026-03-09 | MOSHKEVICH SOLOMON | Officer | Stock Award | 1,774 | - |
| 2026-03-09 | CHAPMAN STEVEN LEONARD | Chief Executive Officer | Stock Award | 5,623 | - |
RABINOWITZ MATTHEW
Officer and Director
2026-04-06
58,292 shares
·
$559,020
MOSHKEVICH SOLOMON
Officer
2026-04-01
3,000 shares
·
$606,899
RABINOWITZ DANIEL A
Officer
2026-04-01
8,400 shares
·
$1,707,814
RABINOWITZ MATTHEW
Officer and Director
2026-03-31
41,708 shares
·
$399,980
SHEENA JONATHAN
Director
2026-03-20
4,570 shares
·
$908,301
RABINOWITZ MATTHEW
Officer and Director
2026-03-16
200,000 shares
·
$38,283,382
RABINOWITZ MATTHEW
Officer and Director
2026-03-16
200,000 shares
·
$1,918,000
CHAPMAN ROWAN E
Director
2026-03-13
122 shares
·
$23,348
MOSHKEVICH SOLOMON
Officer
2026-03-10
915 shares
·
$186,781
CHAPMAN STEVEN LEONARD
Chief Executive Officer
2026-03-10
5,623 shares
·
$1,147,838
RABINOWITZ DANIEL A
Officer
2026-03-10
1,745 shares
·
$356,212
SHEENA JONATHAN
Director
2026-03-10
127 shares
·
$25,925
BROPHY MICHAEL BURKES
Chief Financial Officer
2026-03-10
785 shares
·
$160,244
MOSHKEVICH SOLOMON
Officer
2026-03-09
1,774 shares
CHAPMAN STEVEN LEONARD
Chief Executive Officer
2026-03-09
5,623 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
19 analysts
William Blair
2026-04-14
Outperform
Morgan Stanley
2026-03-03
Overweight
Overweight
Wells Fargo
2026-02-27
Equal-Weight
Equal-Weight
Evercore ISI Group
2026-02-27
Outperform
Outperform
Baird
2026-02-27
Outperform
Outperform
Citigroup
2026-01-07
Buy
Guggenheim
2026-01-05
Buy
Buy
Canaccord Genuity
2025-12-22
Buy
Buy
Barclays
2025-12-15
Overweight
Overweight
JP Morgan
2025-12-15
Overweight
Overweight
Past News Coverage
Recent headlines mentioning NTRA from our newsroom.
Newest → oldest
No matching news yet.